NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
13/07/26	EUR 0.8480	-0.24%	9,554
10/07/26	EUR 0.8500	-4.49%	10,006
09/07/26	EUR 0.8900	+2.30%	1,293
08/07/26	EUR 0.8700	-0.91%	15,839
07/07/26	EUR 0.8780	-0.23%	10,090

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Real-time Euronext Paris Other stock markets 11:30:32 13/07/26 pm AEST			5-day change	1st Jan Change
0.8480 ^EUR	-0.24%		-3.64%	-28.01%

08/07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI
01/07	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain	CI

Market Cap	10.77M 12.31M 9.94M 9.18M 17.41M 1.17B 17.7M 119M 46.62M 579M 46.24M 45.23M 1.99B	P/E 2024	-9.56x	P/E 2025	-4.62x
Enterprise Value	9.15M 10.46M 8.44M 7.8M 14.79M 998M 15.04M 101M 39.61M 492M 39.29M 38.43M 1.69B	EV / Sales 2024	370,592x	EV / Sales 2025	70,790x
Free-Float	85.79%	Yield 2024 *	-	Yield 2025	-

08/07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI
01/07	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain	CI
01/07	NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation
02/06	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	CI
02/06	NFL Biosciences validates breakthrough in personalized medicine
26/05	Glimmers of hope for Middle East peace grow brighter
26/05	NFL Biosciences to File Patent Application for Smoking Cessation Drug-linked Biomarker	MT
26/05	NFL Biosciences files new patent application
26/05	NFL Biosciences Files Patent Application Protecting Predictive Efficacy Biomarker Associated With NFL-101	CI
12/05	NFL Biosciences SA Clarifies Objectives And Evaluation Criteria For Predictive Biomarker Associated With NFL-101	CI
05/05	NFL Biosciences Presents Work On NFL-102 For Smoking Cessation At International Scientific Conferences	CI
16/04	NFL Biosciences SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/04	NFL Biosciences SA announced that it expects to receive ?2.6 million in funding from Vester Finance	CI

21/10/25	Nfl Biosciences Outlines Its Development Plan for Nfl-101 in Smoking Cessation Following Receipt of Scientific Advice from Several European Agencies and the U.S. Fda	CI
02/10/24	NFL Biosciences: Invest Securities reduces its target
15/07/24	NFL Biosciences: Invest Securities raises its target

NFL Biosciences Stock

Stocks

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Valuation: NFL Biosciences

Chart: NFL Biosciences

Latest news : NFL Biosciences

Analysts' recommendations: NFL Biosciences

Press Releases: NFL Biosciences

News in other languages: NFL Biosciences

Quotes and Performance

Course Extremes

Managers and Directors: NFL Biosciences

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

08/07	International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102	BU
01/07	NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain	BU
02/06	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	BU
26/05	NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application	BU
12/05	NFL Biosciences Clarifies the Objectives and Evaluation Criteria for a Predictive Biomarker Associated With NFL-101	BU

08/07	NFL Biosciences : Bilan semestriel du contrat de liquidité
08/07	Reconnaissance scientifique internationale pour NFL Biosciences : 3 présentations retenues au congrès SRNT-Europe 2026, dont une communication orale sur NFL-102
01/07	NFL Biosciences valide la production industrielle du NFL-102 contre la tabagisme
01/07	NFL Biosciences annonce la fabrication avec succès d’un lot clinique GMP de NFL-102 et valide sa chaîne industrielle de production
18/06	NFL Biosciences : compte rendu de l’assemblée générale mixte du 17 juin 2026

1 day	-0.24%
1 week	-3.64%
Current month	-2.53%
1 month	-5.78%
3 months	-22.49%
6 months	-34.57%
Current year	-28.01%

1 week	0.83	0.9
1 month	0.8	0.92
Current year	0.8	1.85
1 year	0.8	1.85
3 years	0.8	3.31
5 years	0.55	5
10 years	0.55	5

Manager	Title	Age	Since
Bruno Lafont CEO	Chief Executive Officer	-	17/10/2024
Guillaume Audema DFI	Director of Finance/CFO	-	-
Violaine Desort Henin CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Ignacio Faus CHM	Chairman	-	27/02/2023
Bruno Lafont CHM	Chairman	-	17/10/2024
Francis Ahner BRD	Director/Board Member	-	19/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NFL BIOSCIENCES	-0.24%	-3.64%	-25.61%	-67.57%	12.31M
WUXI APPTEC CO., LTD.	+1.84%	-0.66%	+59.82%	+94.48%	54.88B
ARGENX SE	-0.31%	-6.13%	+56.59%	+129.40%	54.63B
INSMED INCORPORATED	-2.99%	+1.71%	+11.35%	+441.01%	25.06B
BIONTECH SE	+0.26%	-2.48%	-17.48%	-16.35%	23.14B
WUXI BIOLOGICS (CAYMAN) INC.	-1.69%	-1.27%	+39.51%	-8.30%	19.87B
GENMAB A/S	+1.38%	+3.26%	+37.54%	-27.06%	17.55B
PHARMAESSENTIA CORPORATION	-6.84%	+2.18%	+195.12%	+364.56%	16.5B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.42%	-3.72%	+47.02%	+635.77%	15.75B
EXELIXIS, INC.	-0.72%	+0.61%	+22.58%	+188.74%	14.2B
Average	-1.07%	-0.33%	+42.64%	+173.47%	24.16B
Weighted average by Cap.	-0.52%	-1.45%	+49.58%	+169.69%

	2024	2025
Net sales	46 52.59 42.43 39.19 74.36 5.02K 75.61 506.96 199.08 2.47K 197.46 193.16 8.49K	188 214.93 173.41 160.16 303.9 20.5K 309.01 2.07K 813.64 10.1K 807 789.44 34.72K
Net income	-2.08M -2.38M -1.92M -1.77M -3.36M -227M -3.42M -22.93M -9.01M -112M -8.93M -8.74M -384M	-3.32M -3.79M -3.06M -2.83M -5.36M -362M -5.45M -36.57M -14.36M -178M -14.24M -13.93M -613M
Net Debt	-2.07M -2.37M -1.91M -1.77M -3.35M -226M -3.41M -22.84M -8.97M -111M -8.9M -8.7M -383M	-1.62M -1.85M -1.49M -1.38M -2.62M -177M -2.66M -17.85M -7.01M -86.99M -6.95M -6.8M -299M